How severe is CVE-2018-18977?

CVE-2018-18977 has a CVSS 3.x base score of 7.5, rated high severity. It is exploitable over network with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is high, integrity none, and availability none.

Is CVE-2018-18977 being actively exploited?

It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 2% (73rd percentile), an estimate of the probability of exploitation in the next 30 days.

What products are affected by CVE-2018-18977?

CVE-2018-18977 affects Ascensia Contour Diabetes. See the affected-products list for the exact vulnerable versions.

How do I fix CVE-2018-18977?

Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.

When was CVE-2018-18977 published?

CVE-2018-18977 was published on 2019-05-06 and last updated on 2026-06-17.

CVE-2018-18977

CVE-2018-18977 is a high-severity vulnerability in Ascensia Contour Diabetes with a CVSS 3.x base score of 7.5. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-200.

Key facts

Severity: High (CVSS 3.x base score 7.5)
CVSS v2: 5.0
EPSS exploit prediction: 2% (73rd percentile)
Actively exploited: Not listed in CISA KEV
Weakness: CWE-200
Affected product: Ascensia Contour Diabetes
Published: 2019-05-06
Last modified: 2026-06-17

Description

An issue was discovered in the Ascensia Contour NEXT ONE application for Android before 2019-01-15. An attacker may reverse engineer the codebase to extract sensitive data that contributes to the disclosure of medical information of patients utilizing the Ascensia platform. This occurs because of weak obfuscation.

Frequently asked questions

What is CVE-2018-18977?: An issue was discovered in the Ascensia Contour NEXT ONE application for Android before 2019-01-15. An attacker may reverse engineer the codebase to extract sensitive data that contributes to the disclosure of medical information of patients utilizing the Ascensia platform. This occurs because of weak obfuscation.
How severe is CVE-2018-18977?: CVE-2018-18977 has a CVSS 3.x base score of 7.5, rated high severity. It is exploitable over network with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is high, integrity none, and availability none.
Is CVE-2018-18977 being actively exploited?: It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 2% (73rd percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2018-18977?: CVE-2018-18977 affects Ascensia Contour Diabetes. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2018-18977?: Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
When was CVE-2018-18977 published?: CVE-2018-18977 was published on 2019-05-06 and last updated on 2026-06-17.

References

https://depthsecurity.com/blog/medical-exploitation-you-are-now-diabetic

Affected products (1)

cpe:2.3:a:ascensia:contour_diabetes:*:*:*:*:*:android:*:*

More vulnerabilities in Ascensia Contour Diabetes

CVE-2018-18975 — High (CVSS 7.5): An issue was discovered in the Ascensia Contour NEXT ONE app for iOS before 2019-01-15. An attacker may proxy…
CVE-2018-18979 — High (CVSS 7.4): An issue was discovered in the Ascensia Contour NEXT ONE application for Android before 2019-01-15. It has a statically…
CVE-2018-18978 — High (CVSS 7.4): An issue was discovered in the Ascensia Contour NEXT ONE application for Android before 2019-01-15. It has a statically…
CVE-2018-18976 — Medium (CVSS 5.3): An issue was discovered in the Ascensia Contour NEXT ONE application for iOS and Android before 2019-01-15. An attacker…

All CVEs affecting Ascensia Contour Diabetes →

Other CWE-200 (Exposure of Sensitive Information to an Unauthorized Actor) vulnerabilities

CVE-2026-27604 — Critical (CVSS 10.0): FOSSBilling is a free, open-source billing and client management system. Starting in version 0.5.4 and prior to version…
CVE-2026-40965 — Critical (CVSS 10.0): Cloud Foundry UAA versions v76.12.0 through v78.12.0 are vulnerable to a private key exposure. The server contains a…
CVE-2026-42826 — Critical (CVSS 10.0): Exposure of sensitive information to an unauthorized actor in Azure DevOps allows an unauthorized attacker to disclose…
CVE-2025-29270 — Critical (CVSS 10.0): Incorrect access control in the realtime.cgi endpoint of Deep Sea Electronics devices DSE855 v1.1.0 to v1.1.26 allows…
CVE-2025-61481 — Critical (CVSS 10.0): An issue in MikroTik RouterOS v.7.14.2 and SwOS v.2.18 exposes the WebFig management interface over cleartext HTTP by…
CVE-2025-53624 — Critical (CVSS 10.0): The Docusaurus gists plugin adds a page to your Docusaurus instance, displaying all public gists of a GitHub user.…

Browse all CWE-200 (Exposure of Sensitive Information to an Unauthorized Actor) vulnerabilities →